Eddie Hickman
Stock Analyst at Guggenheim
(4.62)
# 186
Out of 4,966 analysts
17
Total ratings
75%
Success rate
18.67%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $0.85 | - | 4 | Aug 29, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $78 → $84 | $58.58 | +43.39% | 8 | May 2, 2025 | |
| PMN ProMIS Neurosciences | Reiterates: Buy | $6 | $0.54 | +1,011.32% | 2 | Apr 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $9.07 | +142.56% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $13.50 | +137.04% | 1 | Mar 13, 2025 | |
| CYBN Cybin | Initiates: Buy | $35 | $7.48 | +367.91% | 1 | Mar 13, 2025 |
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.85
Upside: -
Tarsus Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $78 → $84
Current: $58.58
Upside: +43.39%
ProMIS Neurosciences
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.54
Upside: +1,011.32%
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $9.07
Upside: +142.56%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $13.50
Upside: +137.04%
Cybin
Mar 13, 2025
Initiates: Buy
Price Target: $35
Current: $7.48
Upside: +367.91%